ARTICLE | Company News

Kyowa, Ultragenyx sell Priority Review voucher for $80.6M

July 31, 2018 5:45 PM UTC

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) revealed that it and partner Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold a rare pediatric disease Priority Review voucher during 2Q18 to an undisclosed company for $80.6 million.

Ultragenyx spokesperson Danielle Keatley declined to name the buyer. The partners split proceeds from the sale evenly...